Expect A Slow Bleed With Portola Pharma
(WorldNews Health)

Portola Pharmaceuticals Inc (PTLA) is a biopharmaceutical company with focus on thrombosis, hematologic disorders and inflammation. The stock has seen substantial boost in share price over the past year, but can this continue or is everything already baked into the price? For a better understanding of the company, it is important to understand their lead programs and the markets they serve. The company has two lead programs which include Betrixaban and Andexanet alfa. These two drugs deal with thrombosis and blood clotting. Dialysis patients are just one group that rely on blood thinners: Source: Shutterstock On June 23, 2017, the FDA approved their drug betrixaban (Bevyxxa) for prophylaxis...